Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291383324> ?p ?o ?g. }
- W4291383324 abstract "Abstract Background Hepatocellular carcinoma (HCC) remains difficult to treat due to limited effective treatment options. While the proteasome inhibitor bortezomib has shown promising preclinical activity in HCC, clinical trials of bortezomib showed no advantage over the standard-of-care treatment sorafenib, highlighting the need for more clinically relevant therapeutic strategies. Here, we propose that rational drug combination design and validation in patient-derived HCC avatar models such as patient-derived xenografts (PDXs) and organoids can improve proteasome inhibitor-based therapeutic efficacy and clinical potential. Methods HCC PDXs and the corresponding PDX-derived organoids (PDXOs) were generated from primary patient samples for drug screening and efficacy studies. To identify effective proteasome inhibitor-based drug combinations, we applied a hybrid experimental-computational approach, Quadratic Phenotypic Optimization Platform (QPOP) on a pool of nine drugs comprising proteasome inhibitors, kinase inhibitors and chemotherapy agents. QPOP utilizes small experimental drug response datasets to accurately identify globally optimal drug combinations. Results Preliminary drug screening highlighted the increased susceptibility of HCC PDXOs towards proteasome inhibitors. Through QPOP, the combination of second-generation proteasome inhibitor ixazomib (Ixa) and CDK inhibitor dinaciclib (Dina) was identified to be effective against HCC. In vitro and in vivo studies demonstrated the synergistic pro-apoptotic and anti-proliferative activity of Ixa + Dina against HCC PDXs and PDXOs. Furthermore, Ixa + Dina outperformed sorafenib in mitigating tumor formation in mice. Mechanistically, increased activation of JNK signaling mediates the combined anti-tumor effects of Ixa + Dina in HCC tumor cells. Conclusions Rational drug combination design in patient-derived avatars highlights the therapeutic potential of proteasome and CDK inhibitors and represents a feasible approach towards developing more clinically relevant treatment strategies for HCC." @default.
- W4291383324 created "2022-08-15" @default.
- W4291383324 creator A5002294653 @default.
- W4291383324 creator A5022627076 @default.
- W4291383324 creator A5025099280 @default.
- W4291383324 creator A5028905834 @default.
- W4291383324 creator A5031239728 @default.
- W4291383324 creator A5035873423 @default.
- W4291383324 creator A5045076272 @default.
- W4291383324 creator A5046309150 @default.
- W4291383324 creator A5054390121 @default.
- W4291383324 date "2022-08-15" @default.
- W4291383324 modified "2023-10-14" @default.
- W4291383324 title "Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors" @default.
- W4291383324 cites W1772903887 @default.
- W4291383324 cites W1874000461 @default.
- W4291383324 cites W1971837077 @default.
- W4291383324 cites W1978735501 @default.
- W4291383324 cites W1981421409 @default.
- W4291383324 cites W1985864219 @default.
- W4291383324 cites W1986141922 @default.
- W4291383324 cites W1989602074 @default.
- W4291383324 cites W1994193851 @default.
- W4291383324 cites W2003425522 @default.
- W4291383324 cites W2008515696 @default.
- W4291383324 cites W2026642838 @default.
- W4291383324 cites W2037986862 @default.
- W4291383324 cites W2052770006 @default.
- W4291383324 cites W2063953032 @default.
- W4291383324 cites W2071430789 @default.
- W4291383324 cites W2072714194 @default.
- W4291383324 cites W2074669321 @default.
- W4291383324 cites W2090926709 @default.
- W4291383324 cites W2091378741 @default.
- W4291383324 cites W2101459399 @default.
- W4291383324 cites W2103562758 @default.
- W4291383324 cites W2106692847 @default.
- W4291383324 cites W2106904404 @default.
- W4291383324 cites W2119807130 @default.
- W4291383324 cites W2123546830 @default.
- W4291383324 cites W2124426490 @default.
- W4291383324 cites W2124560610 @default.
- W4291383324 cites W2131612416 @default.
- W4291383324 cites W2140642045 @default.
- W4291383324 cites W2141444851 @default.
- W4291383324 cites W2145412346 @default.
- W4291383324 cites W2147422161 @default.
- W4291383324 cites W2151305493 @default.
- W4291383324 cites W2154343997 @default.
- W4291383324 cites W2158207366 @default.
- W4291383324 cites W2166427186 @default.
- W4291383324 cites W2172020436 @default.
- W4291383324 cites W2176372762 @default.
- W4291383324 cites W2329380329 @default.
- W4291383324 cites W2343386476 @default.
- W4291383324 cites W2354070186 @default.
- W4291383324 cites W2401985466 @default.
- W4291383324 cites W2467601047 @default.
- W4291383324 cites W2510238988 @default.
- W4291383324 cites W2560499218 @default.
- W4291383324 cites W2580091136 @default.
- W4291383324 cites W2582313469 @default.
- W4291383324 cites W2588471563 @default.
- W4291383324 cites W2600833804 @default.
- W4291383324 cites W2742971656 @default.
- W4291383324 cites W2768999031 @default.
- W4291383324 cites W2771057425 @default.
- W4291383324 cites W2782204860 @default.
- W4291383324 cites W2787358630 @default.
- W4291383324 cites W2789635905 @default.
- W4291383324 cites W2790902804 @default.
- W4291383324 cites W2795708663 @default.
- W4291383324 cites W2809889937 @default.
- W4291383324 cites W2884510934 @default.
- W4291383324 cites W2885322118 @default.
- W4291383324 cites W2898399460 @default.
- W4291383324 cites W2901109482 @default.
- W4291383324 cites W2908573150 @default.
- W4291383324 cites W2946768587 @default.
- W4291383324 cites W2949586081 @default.
- W4291383324 cites W2971404162 @default.
- W4291383324 cites W2972003656 @default.
- W4291383324 cites W2975514178 @default.
- W4291383324 cites W3000993634 @default.
- W4291383324 cites W3013976688 @default.
- W4291383324 cites W3025022288 @default.
- W4291383324 cites W3089599508 @default.
- W4291383324 cites W3094671519 @default.
- W4291383324 cites W3104115968 @default.
- W4291383324 cites W3128646645 @default.
- W4291383324 cites W3133865815 @default.
- W4291383324 cites W3133960718 @default.
- W4291383324 cites W3133992342 @default.
- W4291383324 cites W4242769447 @default.
- W4291383324 doi "https://doi.org/10.1186/s13046-022-02436-9" @default.
- W4291383324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35971164" @default.
- W4291383324 hasPublicationYear "2022" @default.
- W4291383324 type Work @default.
- W4291383324 citedByCount "5" @default.
- W4291383324 countsByYear W42913833242023 @default.